University of Michigan

Amgen Inc.

The University of Texas System

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Elif Arioglu Oral

Simeon I Taylor

Abhimanyu Garg

Alexander M DePaoli

Hakan Oral

Thomas L Chenevert

Barbara McKenna

Charles F Burant

Hero K Hussain

Alex M Depaoli

A Garg

A Univ Texas Southwestern Medical Centre Garg

An ingestible gastric volume reduction device () is provided that is controllably adjustable between an expanded state and a contracted state. A control subsystem within the device is able to selectively transition the device between both states. Such control can be by way of a biological or chemical sensor () in the device, a wireless (RF) receiver (), or timer. Thus activation of the device whether to expand and fill a gastric volume or to contract to open up the gastric volume may be achieved from internal control (within device) or external control (to the device). The device may be used for patient treatment, by administering the device (e.g., through ingestion) to a gastric region and then controllably increasing and/or decreasing the volume of the device during treatment.

Device and system for gastric volume reduction to facilitate weight loss

The invention generally relates to the use of leptin in the treatment of a leptin-responsive disease or condition in a non-lipodystrophic subject. More particularly, the invention is directed to the use of leptin in the treatment of a fatty liver disease in a non-lipodystrophic subject with a relative leptin deficiency. The invention includes methods for the treatment of nonalcoholic steatohepatitis (NASH), alcoholic fatty liver disease (AFLD), and nonalcoholic fatty liver disease (NAFLD) in a non-lipodystrophic subject. The invention includes the treatment of conditions ranging from ectopic lipid accumulation (steatosis) to cirrhosis.

Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects

Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.

Use of leptin to treat metabolic abnormalities associated with lipoatrophy

Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment

Growing community of inventors

Ann Arbor, MI, United States of America

Elif Arioglu Oral